Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: February 2016

Stockton University Names Peter Straub as New Dean of School of Natural Sciences and Mathematics

Galloway, NJ, February 29, 2016 ― Stockton University’s Board of Trustees on February 24 named Peter Straub as dean of the School of Natural Sciences and Mathematics (NAMS).

“The Stockton community is delighted that Dr. Straub was chosen as the best candidate to head NAMS after a nationwide search,” said President Harvey Kesselman.  “Peter is an extraordinary scholar and administrator, and the perfect choice to lead our expansion of the Unified Science Center, which will add to the opportunities for world-class faculty and student research.”

Straub is a Stockton alumnus who received his B.S. in Marine Science in 1980.  He holds an M.S. in Marine Studies from the University of Delaware, where he also earned his Ph.D. in Marine Studies.  Straub did post-doctoral work on Molecular Biology at Washington University in St. Louis. Continue reading

Foundation Aims to Cure Jersey’s Lack of Innovative Health Care

Newark, NJ, February 28, 2016 ― Anjalee Khemlani reports in NJBIZ Safety-net hospitals are like the Cinderellas to their suburban stepsisters, and The Nicholson Foundation is their fairy godmother in New Jersey.

The foundation, in a partnership with the California-based Center for Care Innovations, hosted an innovation fair at the Panasonic U.S. headquarters in Newark last week as part of a multiphase process to identify solutions to common safety-net problems.

Problems include low literacy, low income, language barriers, senior health issues, those without access to personal transportation, as well as identifying vulnerable populations by ZIP codes, according to Veenu Aulakh, co-director of CCI.   Continue reading

Event: NJ Rare Disease Alliance to Commemorate Rare Disease Day 2016 on February 29 in Trenton

Rare Disease DayTrenton, NJ, February 27, 2016 ― The New Jersey Rare Disease Alliance (NJRDA) — dedicated to improving the lives of the more than 800,000 rare disease patients in New Jersey — is hosting an event to observe global Rare Disease Day on Monday, February 29 starting at 10:00 a.m. at the New Jersey Business and Industry Association (NJBIA), 10 West Lafayette Street, Trenton.

Sponsored in conjunction with BioNJ, the HealthCare Institute of New Jersey (HINJ) and the National Organization for Rare Diseases (NORD), training will be provided on how to more effectively build relationships with legislators and other policymakers on behalf of rare disease patients.

Following a NORD-sponsored breakfast at 10:00 a.m. there will be an hour of training from 10:30-11:30 a.m. by state legislative experts from HINJ and BioNJ.  Senator Diane Allen (Burlington) will present a ceremonial resolution commemorating Rare Disease Day 2016 in New Jersey. Continue reading

Rutgers Future Scholars Program Expands to Rahway; Roy Vagelos, Former Merck CEO, Gives $1.75M to Bring Program to Hometown

New Brunswick, NJ, February 27, 2016Rutgers Future Scholars, a pioneer program that for the last eight years has inspired and prepared students in the university’s host communities to attend college, has been extended to include Rahway.

A $1.75 million gift from benefactor P. Roy and Diana Vagelos will allow 15 Rahway students to participate in the program each year for at least the next six years, according to Courtney McAnuff, vice president for enrollment management at Rutgers

“This is a life-changing opportunity for students in Rahway,” McAnuff said. The program will begin taking applications this spring for enrollment in the summer. Rutgers will hold a public interest session for Rahway students March 2. Continue reading

New PhRMA Report Celebrates a Decade of Progress and Innovation in Chronic Diseases

PhRMA Chronic Disease Decade 20160225Washington, DC, February 26, 2016 ― In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases.  With about half of all Americans, or 117 million people, living with one or more chronic health conditions, this innovation is more critical than ever.

Patients with chronic diseases are frequent users of medical care, accounting for 81 percent of hospital admissions and 76 percent of physician visits.

Treating these diseases is hugely expensive with 86 cents of every health care dollar spent in the United States going toward treating chronic illness, and the scope and severity of the problem is only expected to increase.  If left unchecked, chronic diseases could bankrupt the U.S. health care system.

The facts are alarming.  However, a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, “A Decade of Innovation in Chronic Diseases,” highlights several chronic health conditions where significant advances over the past decade have helped patients avoid serious disease complications and hospitalizations, and improved quality of life. Continue reading

Rutgers Cancer Institute’s Michael Gatza Awarded Grant for Research in Ovarian Cancer

Michael Gatza Rutgers Cancer InstNew Brunswick, NJ, February 26, 2016 ― Rutgers Cancer Institute of New Jersey researcher Michael L. Gatza, PhD, has received a $747,000 Pathway to Independence Award from the National Cancer Institute to explore the mechanism behind the development of a subtype of ovarian cancer known as high-grade serous ovarian cancer.

The aim is to identify what drives cell pathway activity so that novel therapeutic strategies can be developed to treat this disease.

According to the American Cancer Society, more than 22,000 new cases of ovarian cancer are expected in 2016 with 14,200 deaths.  Ovarian cancer accounts for five percent of cancer deaths among women in the United States, causing more deaths than any other gynecologic cancer. Continue reading

Christie Administration Continues Investment in New Jersey’s Healthcare System

Chris Christie official portrait 2013Trenton, NJ, February 26, 2016 ― Governor Christie’s Fiscal Year 2017 budget supports New Jersey’s healthcare system with $775.1 million in hospital funding including charity care, medical education and quality improvement.

The proposed budget includes $352 million for charity care, $166.6 million for the hospital incentive program known as Delivery System Reform Incentive Payment (DSRIP) and $188 million for Graduate Medical Education (GME), a $60.7 million increase from last year’s budget to support our teaching hospitals.

The Governor’s proposed budget also includes $24.7 million for Hospital Mental Health Offset Payments and $43.8 million for the support of University Hospital. Continue reading

Rutgers Biotech Startup Earns $500,000 Commitment from Foundation Venture Capital Group

Rutgers 250 AnniversaryNew Brunswick, NJ, February 25, 2016 ― Visikol Inc., a student-run biotech startup from Rutgers University-New Brunswick that markets a technology platform for use in scientific and medical research, has earned a $500,000 commitment from Foundation Venture Capital Group.

Visikol sells a versatile clearing agent, which is a chemical formula that renders tissues transparent, allowing researchers to effectively visualize biological tissues in 3-D.  This approach saves time, reduces structural damage to samples, and enables more information to be gathered from tissues.

Visikol was originally invented to replace chloral hydrate, a controlled substance, for rendering plant tissues transparent. U.S. and European patents for Visikol are pending. Continue reading

U.S. Senate Confirms Dr. Robert Califf to Head FDA

Robert Cadiff FDAWashington, DC, February 24, 2016 ― The United States Senate today confirmed President Barack Obama’s nominee, Dr. Robert Califf, to be commissioner of the Food and Drug Administration (FDA), which is an agency of the U.S. Department of Health and Human Services.

The Senate voted 89-4 to confirm Dr. Califf after one Republican and three Democratic Senators had delayed action in a protest over the agency’s inaction on the abuse of opioid painkillers.

With only a year left in Obama’s presidency, Dr. Califf is tasked with wrapping up the administration’s initiatives at the agency, including unfinished tobacco regulations and food safety and labeling reforms. Continue reading

Seton Hall, HackensackUHN Name Dr. Bonita Stanton as First Medical School Dean

Bonita Stanton Seton Hall med schHackettstown, NJ, February 24, 2016 ― Anjalee Khemlani reports in NJBIZ that Seton Hall University and Hackensack University Health Network announced Dr. Bonita Stanton will be the founding dean of their school of medicine, starting next month.

Dr. Stanton will lead the school, slated to open in fall 2018, with a global view of the medical world.

Dr. Stanton is leaving Michigan, where she was vice dean of research at Wayne State University School of Medicine.

In her years in the industry, Dr. Stanton has worked with many populations in the U.S. and countries such as Bangladesh, China or Egypt, as well as sits on the editorial board of a number of journals. Continue reading